Menu
About your dirty sponges

About your dirty sponges

A kitchen sponge is not y...

Is new cigarette any better?

Is new cigarette any better?

Philip Morris Internation...

Strong: The new beautiful

Strong: The new beautiful

Have you ever just felt s...

2017 Fall movie guide

2017 Fall movie guide

Whoa, September is just a...

Secret life of the banana

Secret life of the banana

On a hot day in June, the...

Flexitarianism: The great uniter?

Flexitarianism: The great uniter?

Can flexitarianism bridge...

10 veggie pizza tips

10 veggie pizza tips

Approximately three billi...

Cake TOO good TO eat . . .

Cake TOO good TO eat . . .

The Seoul-based pastry ch...

Prev Next
Restaurant lunch highlights:

'Startling' cancer therapy results

'Startling' cancer therapy results

The 86 cancer patients were a disparate group, with tumors of the pancreas, prostate, uterus or bone. One woman had a cancer so rare there were no tested treatments. She was told to get her affairs in order.

All the patients carried genetic mutations that disrupted the ability of cells to fix damaged DNA. And all were enrolled in a trial of a drug that helps the immune system attack tumors.

The results, published on Thursday in the journal Science, are so striking that the Food and Drug Administration already has approved the drug,
Just 4 percent of cancer patients have the type of genetic aberration susceptible to pembrolizumab. But that adds up to a lot of patients: as many as 60,000 each year in the United States alone, the study's investigators estimated.

As reported on the New York Times website - READ MORE

Last modified onWednesday, 14 June 2017 05:56
back to top